Apatinib Catalog No.:M10435-10 InChi: InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11

InChi: InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11

Wogonin inhibits β-catenin-mediated transcription through suppressing the activity of CDK8

3-dihydro-1H-isoindol-2-yl)piperidine-2

26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H

Apatinib Catalog No.:M10435-10 InChi: InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11Apatinib, also known as Rivoceranib, is an orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this